Hims & Hers Health, Inc.
corporate_fare Company Profile
Hims & Hers Health, Inc. (NYSE:HIMS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 44 items for HIMS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-11, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for HIMS spans 10-Q, 8-K.
Recent high-impact activity:
- Hims Adds Lilly's Zepbound to Platform, Plans New Peptides After Guidance Cut
- Hims & Hers Cuts 2026 EBITDA Outlook, Q4 Guidance Far Below Consensus; Shares Down 18%
- Hims Cuts 2026 Outlook After Q3 Revenue Miss, Pivots to Branded Weight-Loss Drugs
- Hims & Hers Cuts Full-Year Outlook After Surprise Q3 Loss; Q4 Guidance Misses Consensus
- Hims & Hers 10-Q: $890M Q3 Revenue, $33M Net Loss, $60M FTC Legal Accrual
Financial Snapshot
Short Interest & Short Volume
5.84 days to coverFINRA reported short interest of 51,657,110 shares in HIMS as of the October 30, 2026 settlement, a 3.4% decrease from the prior period — about 5.8 days to cover at its recent average daily volume. On November 20, 2026, 59.6% of HIMS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.